Laboratoire Tilman has acquired Promogen
The shareholders of Promogen have sold the company to Laboratoire Tilman.
Founded in 1956, Laboratoire Tilman is a Belgium pharmaceutical laboratory specialized in the development, production and marketing of phytotherapy products and is the leader in the field of medicinal plants in Belgium. The company offers a range of more than 100 natural herbal solutions sold in over 30 countries, including best-selling products such as Flexofytol, Sedistress and Antimetil.
Founded in 2012, Promogen is an external independent French pharmaceutical network that promotes, sells and distributes a diverse portfolio, which includes medicines, medical devices, food supplements and cosmetics, through four brands, in the rheumatology, well-being, dermo-cosmetics, wound healing and fertility therapeutic areas. Promogen distributes its products to over 9,000 pharmacies and drugstores in France, through an in-house sales force of approximately 40 representatives.
Oaklins’ team in France acted as advisor to the shareholders of Laboratoire Tilman in this transaction.
Talk to the deal team
Related deals
The Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn moreRAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Learn more